Due to advances in our understanding of disease biology, the chance to make a significant difference in the lives of people with ocular disorders has never been greater.
We’re currently focused on diseases of the eye that cause significant vision loss such as wet age-related macular degeneration, geographic atrophy, retinal vein occlusion, diabetic macular edema and diabetic retinopathy, as well as glaucoma. We’re also working on developing medicines to treat vision-threatening orphan diseases that affect smaller patient groups such as familial exudative vitreoretinopathy (FEVR) and Coat's disease.
Our scientists continue to investigate new targets, bringing a wide range of therapeutic platforms to bear, such as bispecific antibodies that can simultaneously neutralize multiple targets and agonist antibodies that can enhance pathways to reverse the course of disease. Always keeping the needs of the patient in mind, we’re also evaluating proprietary technologies for sustained drug delivery through ocular implants, as well as formulations and biodegradable implants. Genentech’s pursuit of personalized therapies extends to the ophthalmology space, where we are looking at specific biomarkers and genetic modifiers.
By leveraging previous research conducted in our immunology, vascular biology and neurobiology groups, and applying it to pathologic conditions of the eye, we hope to shed new light and further our progress in understanding and treating ophthalmic diseases.
Our vision for ophthalmology is simple: Bring breakthrough therapeutics to patients with diseases of the eye that cause significant vision loss.
A quick look at the surprising history and promising future of ophthalmic implants.